Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study

OBJECTIVE: Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (ICI-IA), but there are limited data regarding safety of ICI rechallenge in this setting. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladouceur, Alexandra, Barnetche, Thomas, Mouterde, Gael, Tison, Alice, Bitoun, Samuel, Prey, Sorilla, Dutriaux, Caroline, Gerard, Emilie, Pham-Ledard, Anne, Beylot-Barry, Marie, Zysman, Maeva, Veillon, Rémi, Domblides, Charlotte, Daste, Amaury, Gross-Goupil, Marine, Sionneau, Baptiste, Lefort, Felix, Larroquette, Mathieu, Richez, Christophe, Truchetet, Marie-Elise, Schaeverbeke, Thierry, Kostine, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Inflammatory Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689372/
https://www.ncbi.nlm.nih.gov/pubmed/38030233
http://dx.doi.org/10.1136/rmdopen-2023-003795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689372/
https://www.ncbi.nlm.nih.gov/pubmed/38030233
http://dx.doi.org/10.1136/rmdopen-2023-003795

Ejemplares similares